Harbour BioMed Enters Multi-Year HCAb Technology Licensing Agreement with a Top-Ten Global Pharma for Next Generation Human Antibody Discovery - Yahoo Finance

Harbour BioMed Enters Multi-Year HCAb Technology Licensing Agreement with a Top-Ten Global Pharma for Next Generation Human Antibody Discovery  Yahoo Finance

Technology produces novel heavy chain-only antibodies for bi-specific, single domain antibodies or CAR-Ts.



Comments

Popular posts from this blog

How to Deal with Vaginal Infections and Vaginal Atrophy After Menopause

Shave your pubic hair if you want, but not at these times